Equities
Health CareHealth Care Providers
  • Price (HKD)2.78
  • Today's Change-0.04 / -1.42%
  • Shares traded13.84m
  • 1 Year change-46.12%
  • Beta1.6557
Data delayed at least 15 minutes, as of May 07 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Jinxin Fertility Group Limited is a China-based company principally engaged in the provision of assisted reproductive services (ARS). The Company operates its business through three segments. The ARS segment primarily provides its patients with two treatment solutions: artificial insemination (AI) and in vitro fertilization (IVF) technology. The Management Services segment provides management services to Jinjiang IVF Center and Jinxin Fertility Center. The Ancillary Medical Services segment mainly provides medical services in the areas of gynecology, urology and internal medicine through Shenzhen Zhongshan Hospital. The Company mainly operates its business in China and the Unites.

  • Revenue in HKD (TTM)3.01bn
  • Net income in HKD371.88m
  • Incorporated2003
  • Employees3.27k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
MedSci Healthcare Holdings Ltd376.70m59.38m1.62bn--23.711.1823.624.290.11220.11220.72712.26----------------62.03--15.76----172.010.0041--0.0699--155.11------
EC Healthcare4.10bn-3.74m1.65bn2.72k--0.87632.620.4015-0.0032-0.00323.471.590.76156.2316.481,591,122.000.43157.500.681513.4184.7187.530.566610.240.81441.080.389393.0632.7424.27-64.73-24.2551.5214.87
Rici Healthcare Holdings Ltd3.23bn392.46m1.75bn9.41k4.461.442.590.54190.24680.24682.030.76450.650345.8010.35342,979.208.733.2416.255.7841.7537.0013.435.930.64715.640.67050.0026.0116.8556.06--2.51--
Town Health International Medical Gp Ltd1.83bn-194.21m1.90bn1.40k--0.585--1.03-0.0287-0.02870.27060.47870.396324.254.281,310,249.00-3.44-1.21-4.29-1.4427.3829.06-8.68-4.013.161.030.1121--19.3710.32-1,370.26-----13.65
EuroEyes International Eye Clinic Ltd714.29m131.24m1.93bn290.0014.681.708.762.710.3950.3952.153.410.433623.28114.792,463,066.008.096.189.197.2046.9745.8118.6614.314.53--0.248--17.0412.4446.6929.9134.24--
Mega Genomics Ltd163.22m32.40m2.22bn229.0064.933.2145.5913.610.14450.14450.75192.920.201415.921.01712,750.804.00--4.60--58.36--19.85--5.80--0.07--3.82--270.50------
Chaoju Eye Care Holdings Ltd1.48bn246.95m2.83bn2.60k11.291.087.621.920.35420.35422.123.700.485114.4626.75568,886.907.828.088.809.5645.3543.8116.1215.474.9025.560.077951.5738.3316.7021.9242.68-2.33--
Arrail Group Ltd1.71bn-136.29m3.75bn3.46k--2.0226.452.19-0.2341-0.23413.303.200.496923.7317.73502,627.30-3.98---5.33--17.80---8.00--2.14-16.700.3657---9.23--68.63------
C-Mer Eye Care Holdings Ltd1.92bn62.00m3.79bn3.27k61.152.0512.351.970.04940.04941.531.470.68128.9338.29587,828.903.060.92373.871.1232.1729.954.491.441.7520.200.154--11.0934.98383.427.81----
China Resources Medical Holdings Com Ltd10.90bn277.98m5.48bn20.17k19.240.87485.420.50300.21990.21998.624.840.642324.506.63540,541.502.083.243.494.8018.8620.293.246.600.600523.910.247927.9527.9237.46-3.07-9.7753.23-10.65
Adicon Holdings Ltd3.56bn253.39m6.70bn5.71k27.433.6414.451.880.33580.33584.962.53------622,727.50--------43.49--7.95--1.786.600.3734---32.15---65.50------
Yunkang Group Ltd961.74m-110.32m6.86bn1.51k--3.01--7.13-0.1852-0.18521.573.670.188919.070.4519636,910.90-2.166.70-3.8811.1936.5442.42-11.4310.991.75--0.39619.89-76.278.38-127.10--33.22--
Jinxin Fertility Group Ltd3.01bn371.88m7.78bn3.27k21.330.704811.392.580.13220.13221.104.000.185125.8221.31919,227.002.302.642.723.0142.1541.7612.4414.900.757511.580.214741.5217.9524.78184.6015.6552.59--
Data as of May 07 2024. Currency figures normalised to Jinxin Fertility Group Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

13.22%Per cent of shares held by top holders
HolderShares% Held
HHLR Advisors Ltd.as of 30 Jun 2023176.18m6.39%
The Vanguard Group, Inc.as of 05 Apr 202459.88m2.17%
Norges Bank Investment Managementas of 31 Dec 202328.76m1.04%
China Universal Asset Management Co., Ltd.as of 30 Jun 202321.08m0.76%
BlackRock Fund Advisorsas of 04 Apr 202420.10m0.73%
Bosera Asset Management Co., Ltd.as of 30 Jun 202315.70m0.57%
Dimensional Fund Advisors LPas of 04 Apr 202414.13m0.51%
Penghua Fund Management Co., Ltd.as of 30 Jun 202310.21m0.37%
BC Investment Management Corp.as of 31 Mar 20239.25m0.34%
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 20239.20m0.33%
More ▼
Data from 30 Jun 2023 - 02 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.